Evidence map›Paper›PMID 36627414›Full record

ArticleAAPS PharmSciTech2023

In Vivo Evaluation of Almotriptan malate Formulation through Intranasal Route for the Treatment of Migraine: Systematic Development and Pharmacokinetic Assessment.

Shubham Gupta, Akhil Perla, Abhishek Roy, Jyotsna G Vitore, Bharathi K, Sagar Salave, Dhwani Rana, Amit Sharma, Rajeshwari Rathod, Hemant Kumar and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Shubham GuptaDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Akhil PerlaDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Abhishek RoyDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Jyotsna G VitoreDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Bharathi KDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Sagar SalaveDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Dhwani RanaDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Amit SharmaDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Rajeshwari RathodDepartment of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Hemant KumarDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India.
Derajram BenivalDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Gandhinagar, 382355, India. derajram@niperahm.res.in.
National Institute of Pharmaceutical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine headaches are usually intolerable, and a quick-relief treatment remains an unmet medical need. Almotriptan malate is a serotonin (5-HT

Indexed as

Migraine DisordersSerotonin Receptor AgonistsAdministration, IntranasalAnimalsChromatography, LiquidRatsRats, Sprague-DawleySerotoninTabletsTandem Mass SpectrometryTryptaminesalmotriptanSerotoninSerotonin Receptor AgonistsTabletsTryptamines3-level intranasalalmotriptan malatebioavailabilityCmaxfull factorial designquality-by-design (QbD) approachTmax

Identifiers

PMID36627414
OpenAlexW4315433011

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.